ABBV Oct 2024 180.000 call
| Previous close | 17.89 |
| Open | 19.08 |
| Bid | 20.45 |
| Ask | 21.00 |
| Strike | 180.00 |
| Expiry date | 2024-10-18 |
| Day's range | 15.00 - 19.08 |
| Contract range | N/A |
| Volume | |
| Open interest | 677 |
ZacksTop Stock Reports for Visa, AbbVie & Anheuser-Busch
Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), AbbVie Inc. (ABBV) and Anheuser-Busch InBev SA/NV (BUD), as well as two micro-cap stocks Servotronics, Inc. (SVT) and United-Guardian, Inc. (UG).
ZacksWhy AbbVie (ABBV) Outpaced the Stock Market Today
AbbVie (ABBV) closed the most recent trading day at $196.42, moving +1.56% from the previous trading session.
PR NewswireAbbVie Showcases Advancement of Solid Tumor Pipeline at ESMO 2024, with New Data in Tumor Types with High Unmet Needs
AbbVie (NYSE: ABBV) today announced that new data from its innovative antibody-drug conjugate (ADC) platform will be showcased at the upcoming European Society for Medical Oncology (ESMO) Congress 2024 (September 13-17, 2024). Presentations include data on mirvetuximab soravtansine (ELAHERE®) and c-Met targeting ADCs, telisotuzumab vedotin (Teliso-V) and telisotuzumab adizutecan (ABBV-400). AbbVie's ADCs are designed to target protein biomarkers such as folate receptor-alpha (FRα) and c-Met (MET
